期刊文献+

专家评估在杂质遗传毒性(定量)构效关系评价中的应用

Application of Expert Review in the Evaluation of(Quantitative)Structure-Activity Relationship of the Genotoxicity of Impurities
下载PDF
导出
摘要 目的通过专家评估获得或变更(定量)构效关系[(Q)SAR]评价分类结果实例,提供一种基于人用药品技术要求国际协调理事会(ICH)M7(R1)指导原则进一步利用专家进行评估的杂质遗传毒性评价程序。方法采用Lhasa公司的Nexus 2.5.0版软件平台(整合了Derek Nexus和Sarah Nexus)对杂质进行遗传毒性评价,任意选择3个预测得到阳性、阴性、相互矛盾或未分类结果的实例,进行专家回顾评估,获得最终分类结果。结果实例1,Derek预测结果为阴性,Sarah预测结果为阳性,专家评估后分类结果由3类变更为5类;实例2,Derek预测结果为阴性,Sarah预测结果为模棱两可,专家评估后界定为5类;实例3,Derek和Sarah预测结果均为阴性,专家评估后分类结果由5类变更为1类。结论通过对实例化合物遗传毒性分类结果论证过程的描述,为专家评估在杂质遗传毒性(Q)SAR评价中的应用提供了基本的参考程序。 Objective To provide an evaluation procedure for impurity genotoxicity with expert review based on the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use(ICH)M7(R1)guidelines by examples of(quantitative)structure-activity relationship[(Q)SAR]classification results,which were obtained or modified by using expert evaluation.Methods Nexus 2.5.0 software platform including Derek Nexus and Sarah Nexus provided by Lasha Limited were used to evaluate the genotoxicity of impurities.Three cases of compounds with positive,negative,conflicting or inconclusive prediction results were randomly selected,and experts'review and evaluation were conducted to obtain the final classification results.Results For case 1,Derek prediction result was negative while Sarah prediction result was positive,and the compound should be assigned class 5 instead of class 3 after implementing the expert review.For case 2,Derek prediction result was negative and Sarah prediction result was ambiguous,and the compound was classified into class 5 after implementing the expert review.For case 3,Derek and Sarah prediction results were both negative,and the compound should be assigned class 1 instead of class 5 after implementing the expert review.Conclusion The description of the genotoxicity classification results of example compounds can provide a reference of the basic expert review program in the evaluation of the genotoxicity of impurity by using(Q)SAR.
作者 耿雪 祝清芬 魏霞 苏昕宇 刘娜 钱利民 GENG Xue;ZHU Qingfen;WEI Xia;SU Xinyu;LIU Na;QIAN Limin(Shandong Institute for Food and Drug Control·NMPA Laboratory for Research and Evaluation of Generic Drugs·Shandong Research Center of Engineering and Technology for Consistency Evaluation of Generic Drugs,Jinan,Shandong,China 250101;Shandong University of Traditional Chinese Medicine,Jinan,Shandong,China 250355;The First Affiliated Hospital of Shandong First Medical University·Shandong Provincial Qianfoshan Hospital,Jinan,Shandong,China 250014)
出处 《中国药业》 CAS 2023年第11期48-53,共6页 China Pharmaceuticals
  • 相关文献

参考文献2

二级参考文献39

  • 1王佳佳,徐超,屠云杰,傅正伟,刘维屏.斑马鱼及其胚胎在毒理学中的实验研究与应用进展[J].生态毒理学报,2007,2(2):123-135. 被引量:62
  • 2SNODIN D J, MCCROSSEN SD. Guidelines and pharmacopoe- ial standards for pharmaceutical impurities:Overview and critical assessment[ J ]. Regul Toxicol Pharmacol, 2012,63 ( 2 ) : 298 - 312.
  • 3SUTTER A, AMBERG A, BOYER S, et al. Use of in sillco sys- tems and expert knowledge for structure-based assessment of po- tentially mutagenic impurities [ J ]. Regul Toxicol Pharmacol, 2013, 67(1) :39 -52.
  • 4ICH. M7 : Assessment and Control. of DNA Reactive (. Mutagemc) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk[ S]. 2010.
  • 5ICH.S2 ( R1 ) : Genotoxieity Testing and Data Interpretation for Pharmaceuticals for Human Use[ S]. 2012.
  • 6EMEA. Guideline on the Limits of Genotoxic Impurities[ S ]. 2006.
  • 7EMEA. Questions and Answers on the Guidance on the Limits of Geuotoxic impurities[ S ]. 2010.
  • 8FDA. Guidance for Industry, Genotoxic and Carcinogenic Impuri- ties in Drug Substances and Products:Recommended Approaches I sl. 2008.
  • 9BENIGNI R. Structures alerts for carcinegenicity and the Salme- nella assay system : A novel insight through the chemical relational databases technology [ J ]. Mulation Res, 2008,659 ( 3 ) : 248 -261.
  • 10MCCARREN P, BEBERNITZ GR, GEDECK P, et al. Avoidance of the Ames Test liability for aryl-amines via computation [ J ]. Bioorg Med Chem,2011,19(10 ) :3173 -3182.

共引文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部